Pulmonary metastasectomy in the era of targeted therapy and immunotherapy.
Pulmonary metastasectomy in the era of targeted therapy and immunotherapy.
复制标题
DOI：
10.21037/jtd.2020.03.120
复制
发表时间：
2021-04
影响因子：
2.5
通讯作者：
Chua TC
中科院分区：
文献类型：
--
作者：
Bong CY;Smithers BM;Chua TC
转移性黑色素瘤是一种致死性恶性肿瘤，具有较高的死亡率和发病率。自20世纪70年代初以来，可用的药物治疗在提高生存率方面受到限制。手术是治愈的最好机会。然而，只能为选定的患者提供手术。自从引入靶向和免疫疗法（包括BRAF和MEK抑制剂）以及检查点阻断剂（如PD-1和CTLA-4抗体）以来，目前的治疗前景已经发生了根本性的变化。这些新疗法的生存率与手术相当，在某些情况下甚至超过了手术。抗PD 1和CTLA-4联合治疗与严重的副作用有关，BRAF和MEK抑制剂联合治疗可能引发初始肿瘤反应，但长期使用导致耐药肿瘤克隆和疾病复发。本文综述了在目前有效的靶向治疗和免疫治疗的情况下，肺肿瘤切除术对恶性黑色素瘤肺转移的作用。
Metastatic melanoma is a fatal malignancy with a high mortality and morbidity. Since the early 1970s, available medical therapies were limited in improving survival. Surgery represented the best chance for a cure. However, surgery could only be offered to selected patients. The current landscape of treatment has radically evolved since the introduction of targeted and immunotherapies including BRAF and MEK inhibitors, and checkpoint blockers, like PD-1 and CTLA-4 antibodies. These new therapies have seen survival rates matching, and in some cases surpassing, that of surgery. Anti-PD1 and CTLA-4 combination treatments are associated with severe side effects and BRAF and MEK inhibitor combinations may trigger initial tumour responses but prolonged use have resulted in the development of resistant tumour clones and disease relapse. This review examines the role of pulmonary metastasectomy for lung metastasis from malignant melanoma in the current landscape of effective targeted therapy and immunotherapy.
影响因子：
8.8
作者：
Johnston, S R;Constenla, D O;Moore, J;Atkinson, H;A'Hern, R P;Dadian, G;Riches, P G;Gore, M E
通讯作者：
Gore, M E